Main Article Content
Introduction: For the management of the COVID-19, systemic glucocorticoids are given. The fungal infections of these patients are increasingly being reported. Hence in this study we intend to conduct a systemic review about the cases reported of the Mucormycosis. Material and method: Online data was collected from the search engines of EBSCO, Pubmed, Google Scholar, Scopus. The searched terms were COVID 19, CORONA, SARS-CoV-2, fungal infections, Mucormycosisetc. The study articles were collected that from Jan 2020 to May 2021. Based on the PICOS guidelines the systemic review was performed. Results: From a total of 20 articles on the post COVID fungal infections, only 9 articles were considered for the study that fit the criteria of mucormycosis. There was a significant association seen between the comorbidities and the treatment done for the COVID19 that may have been resulted in the fungal infection.
Conclusion: Patients with diabetes mellitus and multiple risk factors may be at a greater risk for being infected with the mucormycosis. Simultaneous glucocorticoid therapy may increase the risk of mucormycosis. A high index of suspicion and aggressive management is required to improve outcomes.